Skip to content
Subscriber Only
Opinion
Max Nisen

There's a Middle Ground in Amgen's Drug-Price Battle

Repatha sales would benefit if the company and payers were a little more flexible.

The February news that Amgen Inc.'s cholesterol-lowering drug Repatha helped prevent heart attacks was one of the most exciting biotech events of the year, renewing faith in the drug's blockbuster potential. 

But the full trial results behind that headline, which Amgen released on Friday, disappointed investors, sinking the company's shares more than 6 percent.